Cargando…
Development and Validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
PURPOSE: The purpose of this study was to develop Korean versions of the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy (NCCN-FACT) Ovarian Symptom Index-18 (NFOSI-18) and FACT/Gynecologic Oncology Group (FACT-GOG) Neurotoxicity 4-item (NTX-4), evaluating their reliabi...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333974/ https://www.ncbi.nlm.nih.gov/pubmed/29510610 http://dx.doi.org/10.4143/crt.2017.361 |
_version_ | 1783387647989776384 |
---|---|
author | Lee, Maria Lee, Yumi Kim, Kidong Park, Eun Young Lim, Myong Cheol Kim, Jung-Sup Kim, Hee Seung Kim, Yong-Beom Kim, Yong-Man Joo, Jungnam Park, Sang Yoon Choi, Chel Hun Kim, Jae-Hoon |
author_facet | Lee, Maria Lee, Yumi Kim, Kidong Park, Eun Young Lim, Myong Cheol Kim, Jung-Sup Kim, Hee Seung Kim, Yong-Beom Kim, Yong-Man Joo, Jungnam Park, Sang Yoon Choi, Chel Hun Kim, Jae-Hoon |
author_sort | Lee, Maria |
collection | PubMed |
description | PURPOSE: The purpose of this study was to develop Korean versions of the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy (NCCN-FACT) Ovarian Symptom Index-18 (NFOSI-18) and FACT/Gynecologic Oncology Group (FACT-GOG) Neurotoxicity 4-item (NTX-4), evaluating their reliability and reproducibility. MATERIALS AND METHODS: In converting NFOSI-18 and NTX-4, the following steps were performed: forward translation, backward translation, expert review, pretest of preliminary format, and finalization of Korean versions (K-NFOSI-18 and K-NTX-4). Patients were enrolled from six institutions where each had completed chemotherapy for ovarian, tubal, or peritoneal cancer at least 1 month earlier. In addition to demographics obtained by questionnaire, all subjects were assessed via K-NFOSI-18, K-NTX-4, and a Korean version of the EuroQoL-5 Dimension. Internal structural validity and reliability were evaluated using item internal consistency, item discriminant validity, and Cronbach's α. To evaluate test-retest reliability, K-NFOSI-18 and K-NTX-4 were readministered after 7-21 days, and intraclass correlation coefficients (ICCs) were calculated. RESULTS: Of the 250 women enrolled during the 3-month recruitment period, 13 withdrew or did not respond, leaving 237 (94.8%) for the analyses. Mean patient age was 54.3±10.8 years. Re-testing was performed in 190 patients (80.2%). The total K-NFOSI-18 and K-NTX-4 scores were 49 (range, 20 to 72) and 9 (range, 0 to 16), respectively, with high reliability (Cronbach's α=0.84 and 0.89, respectively) and reproducibility (ICC=0.77 and 0.84, respectively) achieved in retesting. CONCLUSION: Both NFOSI-18 and NTX-4 were successfully developed in Korean with minimal modification. Each Korean version showed high internal consistency and reproducibility. |
format | Online Article Text |
id | pubmed-6333974 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Korean Cancer Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-63339742019-01-22 Development and Validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Lee, Maria Lee, Yumi Kim, Kidong Park, Eun Young Lim, Myong Cheol Kim, Jung-Sup Kim, Hee Seung Kim, Yong-Beom Kim, Yong-Man Joo, Jungnam Park, Sang Yoon Choi, Chel Hun Kim, Jae-Hoon Cancer Res Treat Original Article PURPOSE: The purpose of this study was to develop Korean versions of the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy (NCCN-FACT) Ovarian Symptom Index-18 (NFOSI-18) and FACT/Gynecologic Oncology Group (FACT-GOG) Neurotoxicity 4-item (NTX-4), evaluating their reliability and reproducibility. MATERIALS AND METHODS: In converting NFOSI-18 and NTX-4, the following steps were performed: forward translation, backward translation, expert review, pretest of preliminary format, and finalization of Korean versions (K-NFOSI-18 and K-NTX-4). Patients were enrolled from six institutions where each had completed chemotherapy for ovarian, tubal, or peritoneal cancer at least 1 month earlier. In addition to demographics obtained by questionnaire, all subjects were assessed via K-NFOSI-18, K-NTX-4, and a Korean version of the EuroQoL-5 Dimension. Internal structural validity and reliability were evaluated using item internal consistency, item discriminant validity, and Cronbach's α. To evaluate test-retest reliability, K-NFOSI-18 and K-NTX-4 were readministered after 7-21 days, and intraclass correlation coefficients (ICCs) were calculated. RESULTS: Of the 250 women enrolled during the 3-month recruitment period, 13 withdrew or did not respond, leaving 237 (94.8%) for the analyses. Mean patient age was 54.3±10.8 years. Re-testing was performed in 190 patients (80.2%). The total K-NFOSI-18 and K-NTX-4 scores were 49 (range, 20 to 72) and 9 (range, 0 to 16), respectively, with high reliability (Cronbach's α=0.84 and 0.89, respectively) and reproducibility (ICC=0.77 and 0.84, respectively) achieved in retesting. CONCLUSION: Both NFOSI-18 and NTX-4 were successfully developed in Korean with minimal modification. Each Korean version showed high internal consistency and reproducibility. Korean Cancer Association 2019-01 2018-03-07 /pmc/articles/PMC6333974/ /pubmed/29510610 http://dx.doi.org/10.4143/crt.2017.361 Text en Copyright © 2019 by the Korean Cancer Association This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Lee, Maria Lee, Yumi Kim, Kidong Park, Eun Young Lim, Myong Cheol Kim, Jung-Sup Kim, Hee Seung Kim, Yong-Beom Kim, Yong-Man Joo, Jungnam Park, Sang Yoon Choi, Chel Hun Kim, Jae-Hoon Development and Validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
title | Development and Validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
title_full | Development and Validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
title_fullStr | Development and Validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
title_full_unstemmed | Development and Validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
title_short | Development and Validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
title_sort | development and validation of ovarian symptom index-18 and neurotoxicity-4 for korean patients with ovarian, fallopian tube, or primary peritoneal cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333974/ https://www.ncbi.nlm.nih.gov/pubmed/29510610 http://dx.doi.org/10.4143/crt.2017.361 |
work_keys_str_mv | AT leemaria developmentandvalidationofovariansymptomindex18andneurotoxicity4forkoreanpatientswithovarianfallopiantubeorprimaryperitonealcancer AT leeyumi developmentandvalidationofovariansymptomindex18andneurotoxicity4forkoreanpatientswithovarianfallopiantubeorprimaryperitonealcancer AT kimkidong developmentandvalidationofovariansymptomindex18andneurotoxicity4forkoreanpatientswithovarianfallopiantubeorprimaryperitonealcancer AT parkeunyoung developmentandvalidationofovariansymptomindex18andneurotoxicity4forkoreanpatientswithovarianfallopiantubeorprimaryperitonealcancer AT limmyongcheol developmentandvalidationofovariansymptomindex18andneurotoxicity4forkoreanpatientswithovarianfallopiantubeorprimaryperitonealcancer AT kimjungsup developmentandvalidationofovariansymptomindex18andneurotoxicity4forkoreanpatientswithovarianfallopiantubeorprimaryperitonealcancer AT kimheeseung developmentandvalidationofovariansymptomindex18andneurotoxicity4forkoreanpatientswithovarianfallopiantubeorprimaryperitonealcancer AT kimyongbeom developmentandvalidationofovariansymptomindex18andneurotoxicity4forkoreanpatientswithovarianfallopiantubeorprimaryperitonealcancer AT kimyongman developmentandvalidationofovariansymptomindex18andneurotoxicity4forkoreanpatientswithovarianfallopiantubeorprimaryperitonealcancer AT joojungnam developmentandvalidationofovariansymptomindex18andneurotoxicity4forkoreanpatientswithovarianfallopiantubeorprimaryperitonealcancer AT parksangyoon developmentandvalidationofovariansymptomindex18andneurotoxicity4forkoreanpatientswithovarianfallopiantubeorprimaryperitonealcancer AT choichelhun developmentandvalidationofovariansymptomindex18andneurotoxicity4forkoreanpatientswithovarianfallopiantubeorprimaryperitonealcancer AT kimjaehoon developmentandvalidationofovariansymptomindex18andneurotoxicity4forkoreanpatientswithovarianfallopiantubeorprimaryperitonealcancer |